Alpha 2.0

» Articles » PMID: 37432317

Measurement of Serum Low Density Lipoprotein Cholesterol and Triglyceride-Rich Remnant Cholesterol As Independent Predictors of Atherosclerotic Cardiovascular Disease: Possibilities and Limitations

Overview

Overview

Journal Nutrients

Date 2023 Jul 11

PMID 37432317

Authors

Authors

Dieter Lutjohann

Hans-Ulrich Klor

Frans Stellaard

Affiliations

Affiliations

Soon will be listed here.

Abstract

The serum low density lipoprotein cholesterol (LDL-C) concentration is the dominant clinical parameter to judge a patient's risk of developing cardiovascular disease (CVD). Recent evidence supports the theory that cholesterol in serum triglyceride-rich lipoproteins (TRLs) contributes significantly to the atherogenic risk, independent of LDL-C. Therefore, combined analysis of both targets and adequate treatment may improve prevention of CVD. The validity of TRL-C calculation is solely dependent on the accuracy of the LDL-C measurement. Direct measurement of serum LDL- C is more accurate than established estimation procedures based upon Friedewald, Martin-Hopkins, or Sampson equations. TRL-C can be easily calculated as total C minus high density lipoprotein C (HDL-C) minus LDL-C. Enhanced serum LDL-C or TRL-C concentrations require different therapeutic approaches to lower the atherogenic lipoprotein C. This review describes the different atherogenic lipoproteins and their possible analytical properties and limitations.

Citing Articles

Phytosterol-Enriched Dietary Supplements for Lowering Plasma LDL-Cholesterol: Yes or No?.

Stellaard F, Lutjohann D Nutrients. 2025; 17(4).

PMID: 40004982 PMC: 11858453. DOI: 10.3390/nu17040654.

Melatonin as an adjunctive therapy in cardiovascular disease management.

Luo Z, Tang Y, Zhou L Sci Prog. 2024; 107(4):368504241299993.

PMID: 39574322 PMC: 11585022. DOI: 10.1177/00368504241299993.

Causal association between remnant cholesterol level and risk of cardiovascular diseases: a bidirectional two sample mendelian randomization study.

Zhong L, Xie B, Wang H, Ji X Sci Rep. 2024; 14(1):27038.

PMID: 39511362 PMC: 11544147. DOI: 10.1038/s41598-024-78610-0.

Exploration of Risk Factors for Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Retrospective Study.

Feng M, Meng F, Jia Y, Wang Y, Ji G, Gao C Inflammation. 2024; .

PMID: 39414673 DOI: 10.1007/s10753-024-02157-5.

Relationship between Vitamin D3 Deficiency, Metabolic Syndrome and , and Gene Polymorphisms.

Stroia C, Ghitea T, Vranceanu M, Muresan M, Bimbo-Szuhai E, Pallag C Nutrients. 2024; 16(9).

PMID: 38732523 PMC: 11085312. DOI: 10.3390/nu16091272.

References

1.

Cantey E, Wilkins J . Discordance between lipoprotein particle number and cholesterol content: an update. Curr Opin Endocrinol Diabetes Obes. 2018; 25(2):130-136. DOI: 10.1097/MED.0000000000000389. View

2.

Paquette M, Amyot J, Fantino M, Baass A, Bernard S . Rare Variants in Triglycerides-Related Genes Increase Pancreatitis Risk in Multifactorial Chylomicronemia Syndrome. J Clin Endocrinol Metab. 2021; 106(9):e3473-e3482. DOI: 10.1210/clinem/dgab360. View

3.

Johannesen C, Mortensen M, Langsted A, Nordestgaard B . Apolipoprotein B and Non-HDL Cholesterol Better Reflect Residual Risk Than LDL Cholesterol in Statin-Treated Patients. J Am Coll Cardiol. 2021; 77(11):1439-1450. DOI: 10.1016/j.jacc.2021.01.027. View

4.

Sniderman A, Thanassoulis G, Glavinovic T, Navar A, Pencina M, Catapano A . Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review. JAMA Cardiol. 2019; 4(12):1287-1295. PMC: 7369156. DOI: 10.1001/jamacardio.2019.3780. View

5.

Yang J, Wang Y, Xi Z, Ma Y, Shao C, Wang W . Remnant-Like Particle Cholesterol and the Risk of Major Adverse Cardiovascular Events: A Systematic Review and Meta-Analysis. J Cardiovasc Dev Dis. 2022; 9(12). PMC: 9781984. DOI: 10.3390/jcdd9120452. View

6.

Avenell A, Robertson C, Skea Z, Jacobsen E, Boyers D, Cooper D . Bariatric surgery, lifestyle interventions and orlistat for severe obesity: the REBALANCE mixed-methods systematic review and economic evaluation. Health Technol Assess. 2018; 22(68):1-246. PMC: 6296173. DOI: 10.3310/hta22680. View

7.

Langlois M, Sniderman A . Non-HDL Cholesterol or apoB: Which to Prefer as a Target for the Prevention of Atherosclerotic Cardiovascular Disease?. Curr Cardiol Rep. 2020; 22(8):67. DOI: 10.1007/s11886-020-01323-z. View

8.

Jae S, Kim H, Kunutsor S, Bunsawat K, Kurl S, Laukkanen J . Associations of Cardiorespiratory Fitness With Estimated Remnant Cholesterol and Non-High-Density Lipoprotein Cholesterol in Healthy Men. Am J Cardiol. 2022; 186:170-175. DOI: 10.1016/j.amjcard.2022.09.022. View

9.

Patnaik S, Pollevick M, Lara-Breitinger K, Stone N . Inter-Individual Variability in Lipid Response: A Narrative Review. Am J Med. 2022; 135(12):1427-1433.e7. DOI: 10.1016/j.amjmed.2022.06.018. View

10.

Miller M, Ginsberg H, Schaefer E . Relative atherogenicity and predictive value of non-high-density lipoprotein cholesterol for coronary heart disease. Am J Cardiol. 2008; 101(7):1003-8. DOI: 10.1016/j.amjcard.2007.11.046. View

11.

Kumari A, Kristensen K, Ploug M, Lund Winther A . The Importance of Lipoprotein Lipase Regulation in Atherosclerosis. Biomedicines. 2021; 9(7). PMC: 8301479. DOI: 10.3390/biomedicines9070782. View

12.

Calvier L, Herz J, Hansmann G . Interplay of Low-Density Lipoprotein Receptors, LRPs, and Lipoproteins in Pulmonary Hypertension. JACC Basic Transl Sci. 2022; 7(2):164-180. PMC: 8897182. DOI: 10.1016/j.jacbts.2021.09.011. View

13.

Kumar A, Chauhan S . Pancreatic lipase inhibitors: The road voyaged and successes. Life Sci. 2021; 271:119115. DOI: 10.1016/j.lfs.2021.119115. View

14.

Jacobson T . Opening a new lipid "apo-thecary": incorporating apolipoproteins as potential risk factors and treatment targets to reduce cardiovascular risk. Mayo Clin Proc. 2011; 86(8):762-80. PMC: 3146376. DOI: 10.4065/mcp.2011.0128. View

15.

HAVEL R . Remnant lipoproteins as therapeutic targets. Curr Opin Lipidol. 2000; 11(6):615-20. DOI: 10.1097/00041433-200012000-00008. View

16.

Koren E, Corder C, Mueller G, Centurion H, Hallum G, Fesmire J . Triglyceride enriched lipoprotein particles correlate with the severity of coronary artery disease. Atherosclerosis. 1996; 122(1):105-15. DOI: 10.1016/0021-9150(95)05791-9. View

17.

Gitt A, Parhofer K, Laufs U, Marz W, Paar W, Bramlage P . Hypercholesterolemia diagnosis, treatment patterns and target achievement in patients with acute coronary syndromes in Germany. Clin Res Cardiol. 2022; 112(2):299-311. DOI: 10.1007/s00392-022-02108-w. View

18.

Kuklenyik Z, Jones J, Gardner M, Schieltz D, Parks B, Toth C . Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry. PLoS One. 2018; 13(4):e0194797. PMC: 5892890. DOI: 10.1371/journal.pone.0194797. View

19.

Tian Y, Wu W, Qin L, Yu X, Cai L, Wang H . Prognostic value of remnant cholesterol in patients with coronary heart disease: A systematic review and meta-analysis of cohort studies. Front Cardiovasc Med. 2023; 9:951523. PMC: 9892060. DOI: 10.3389/fcvm.2022.951523. View

20.

Werner C, Laufs U . Moving beyond the "LDL hypothesis". Vasa. 2015; 44(5):333-40. DOI: 10.1024/0301-1526/a000451. View